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Abstract
Background: Low skeletal muscle mass is associated with insulin resistance and metabolic syndrome. Serum 
creatinine may serve as a surrogate marker of muscle mass, and a possible relationship between low serum creatinine 
and type 2 diabetes has recently been demonstrated. We aimed to validate this finding in a population of Caucasian 
morbidly obese subjects.
Methods: Cross-sectional study of 1,017 consecutive morbidly obese patients with an estimated glomerular filtration 
rate >60 ml/min/1.73 m2. Logistic regression (univariate and multiple) was used to assess the association between 
serum creatinine and prevalent type 2 diabetes, including statistically testing for the possibility of non-linearity in the 
relationship by implementation of Generalized Additive Models (GAM) and piecewise linear regression. Possible 
confounding variables such as age, family history of diabetes, waist-to-hip ratio, hypertension, current smoking, serum 
magnesium, albuminuria and insulin resistance (log HOMA-IR) were adjusted for in three separate multiple logistic 
regression models.
Results: The unadjusted GAM analysis suggested a piecewise linear relationship between serum creatinine and 
diabetes. Each 1 μmol/l increase in serum creatinine was associated with 6% (95% CI; 3%-8%) and 7% (95% CI; 2%-13%) 
lower odds of diabetes below serum creatinine levels of 69 and 72 μmol/l in women and men, respectively. Above 
these breakpoints the serum creatinine concentrations did not reduce the odds further. Adjustments for non-
modifiable and modifiable risk factors left the piecewise effect for both women and men largely unchanged. In the 
fully adjusted model, which includes serum magnesium, albuminuria and log HOMA-IR, the piecewise effect for men 
was statistically non-significant, but it remained present for women. Patients with creatinine levels below median had 
approximately 50% (women) and 75% (men) increased odds of diabetes.
Conclusions: Low serum creatinine is a predictor of type 2 diabetes in Caucasian morbidly obese patients, 
independent of age, gender, family history of diabetes, anthropometric measures, hypertension, and current smoking. 
Longitudinal studies of both obese and non-obese populations are needed to investigate whether serum creatinine 
may be causally linked with type 2 diabetes, and if so, precisely how they are linked.
Background
Obesity and insulin resistance are well established risk
factors for type 2 diabetes mellitus (T2DM) [1,2]. Skeletal
muscle is the most important site of insulin resistance
and accounts for approximately 90% of overall glucose
disposal after glucose infusion [3]. Muscle mass has been
shown to be inversely associated with insulin resistance
[4] and the metabolic syndrome [5]. Conversely, Kuk et al.
found that whole-body skeletal muscle mass was not
associated with either glucose tolerance or insulin sensi-
tivity in overweight and obese men and women [6]. Crea-
tinine is the only metabolite of creatine which is mainly
(98%) located in striated muscle [7], and 24-h urinary cre-
atinine excretion is highly correlated with muscle mass
estimates by dual-energy X-ray absorptiometry [8]. Since
serum creatinine is highly correlated with 24-h urine
excretion (r = 0.82, p < 0.0001) in subjects with normal
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Page 2 of 6renal function [9], it may represent an acceptable and eas-
ily measured surrogate marker of muscle mass.
Low serum creatinine levels were associated with a
higher risk of T2DM in a recent study of non-obese mid-
dle-aged Japanese men [10], leading the authors to specu-
late that low creatinine might reflect low muscle mass
volume. In addition, glomerular hyperfiltration, which is
associated with lower serum creatinine levels, may be
associated with increased metabolic risk [11] and future
diabetes [12]. Notably, obesity may be considered as a
state of relative hyperfiltration, and several lines of evi-
dence indicate that the absolute glomerular filtration rate
(GFR) is higher in severely obese subjects than in their
lean counterparts [13,14].
We aimed to explore whether serum creatinine is a pre-
dictor of T2DM among morbidly obese Caucasian
women and men.
Methods
Study population, data collection and ethics
The present analysis is based on data from a previously
published cross-sectional study of the relationship
between PTH and the metabolic syndrome [15]. Briefly, a
total of 1,017 consecutive Caucasian morbidly obese
patients who attended our tertiary care center between
2005 and 2008 were included in the analysis. All patients
had an estimated glomerular filtration rate (eGFR) > 60
ml/min/1.73 m2 [16]. The study was approved by the
Regional Committee for Medical Research Ethics (S-
05175) and was performed in accordance with the Decla-
ration of Helsinki [17].
T2DM was diagnosed in patients who had a prior his-
tory of T2DM or a fasting serum glucose level ≥ 7.0
mmol/l [18]. Homeostasis Model Assessment Insulin
Resistance (HOMA- IR) was calculated as ([fasting serum
glucose (mmol/l) * fasting serum insulin (pmol/l)]/135)
[19]. The log (HOMA-IR) is presented both because it
has a stronger linear correlation with glucose clamp esti-
mates of insulin sensitivity and because it is useful for the
evaluation of insulin resistance in glucose intolerant indi-
viduals, those with mild to moderate diabetes, and those
with other insulin-resistant conditions [20].
Lean body weight (LBW) was estimated with gender
specific equations which have been validated in extremely
obese subjects [21]. LBW (male) = (9270*body weight)/
(6680+216*BMI) and LBW (female) = (9270*body
weight)/(8780+244*BMI).
The modified Cockcroft-Gault formula (replacing body
weight with LBW), which may be appropriate to estimate
creatinine clearance in morbidly obese subjects, was
implemented in the analysis [22]. It seems superior to the
MDRD equation, and it provides a precise and accurate
estimate of 24-hour measured creatinine clearance; Crea-
tinine clearance (ml/min) = (140-age)*LBW*serum cre-
atine*1.23*0.85 (if female) [22]. Albuminuria was defined
as present if the albumin/creatinine ratio was ≥ 2.5 mg/
mmol in men and ≥ 3.5 mg/mmol in women [23].
Questionnaire physical activity
A sub-group of 495 consecutive patients (recruited
between May 07th 2007 and September 16th 2008) com-
pleted a physical activity questionnaire which has been
validated by a Norwegian population based epidemiolog-
ical study [24]. Patients were asked, "How has your lei-
sure-time physical activity been during the last year?"
Light activity was defined as no sweating or being out of
breath. Hard physical activity was defined as sweating/
being out of breath. Duration was classified as hours per
week: None, <1, 1-2, 3 and more.
Laboratory analyses
After an overnight fast blood samples were obtained by
venipuncture in vacutainer gel tubes and serum separated
from cells within 2 hours. Analyses of serum creatinine,
glucose, magnesium and CRP were performed using dry
reagent slide technology on the Vitros 950 Analyzer/Vit-
ros FS 5.1 (Ortho-Clinical Diagnostics, New York, USA).
The interassay coefficient of variation for creatinine was
2%. Urine-albumin was analyzed using an immunochem-
ical turbidimetric method (Konelab 60i, Thermo Electron
Corporation, Helsinki, Finland). Insulin was analyzed in
serum using radioimmunoassay (Linco Research Inc, St.
Charles, MO). The interassay coefficient of variation for
insulin was 8%.
Statistical analysis
Data are given as mean (standard deviation; SD) or pro-
portions (%) unless otherwise stated. When required,
skewed data was log-transformed in order to approxi-
mate normality before statistical analyses. Differences
between groups were analyzed using independent sam-
ples t-test for continuous data, whilst χ2 was used for cat-
egorical data. Spearman's correlation was calculated to
assess bivariate correlations between continuous vari-
ables. 95% Confidence Intervals (CI) were constructed
using bootstrapping.
Women and men were analysed separately due to the
known differences in skeletal muscle mass and serum
creatinine.
Logistic regression with predefined explanatory vari-
ables was used to assess the odds of T2DM. Expecting
non-linearity in the relationship between creatinine and
T2DM we also fitted Generalized Additive Models
(GAM) [25]. GAM is a natural extension of Generalized
Linear Models (GLM), e.g. logistic regression, and allows
for all types of functional relationships between depen-
dent and independent variables using splines. As creati-
nine appeared to be piecewise linear with respect to
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regression models for all of the increasingly complex
models described below, i.e. estimating the existence and
location of a possible breakpoint in the relationship
between creatinine and T2DM [26].
We fitted one crude (unadjusted) logistic regression
model (model 1) and three separate multiple logistic
regression models (models 2-4) for T2DM (yes/no) as the
dependent variable. In model 1 serum creatinine as a
continuous or dichotomized variable was entered into a
logistic regression analysis (no missing values). In model
2 the non-modifiable risk factors age and family history
of diabetes were added to model 1 (one missing value). In
model 3 the modifiable risk factors; WHR, hypertension
and current smoking; were added to model 2 (WHR was
substituted for either BMI or lean body weight in supple-
mentary analyses; <1% missing values). Finally, in model 4
other clinically relevant risk factors for T2DM; serum
magnesium [27], albuminuria [28,29] and insulin resis-
tance (log [HOMA-IR]); were added to model 3 (8% miss-
ing values). A 5% statistical significance level was chosen.
The analyses were implemented using SPSS 16.0 (SPSS,
Chicago, IL) and R 2.9.0 [30].
Results
Clinical characteristics and risk factors according to gen-
der and presence or absence of T2DM are shown in table
1 (Additional file 1). Out of the 1,017 consecutive mor-
bidly obese subjects who took part in the study a total of
156 women (23%) and 106 men (32%) had T2DM (p =
0.002 for the difference). When compared to their non-
diabetic counterparts the serum creatinine levels of dia-
betic patients were significantly lower. By contrast, creati-
nine clearance did not differ significantly between
groups.
Serum creatinine had a weak negative correlation with
WC (r = -0.08, 95% CI; -0.16 to -0.01), WHR(r = -0.08,
95% CI; -0.16 to -0.02) and BMI (r = -0.08, 95% CI; -0.16
to -0.01) in women, but only with BMI in men (r = -0.11,
95% CI; -0.22 to -0.01). Serum creatinine did not correlate
significantly with lean body weight (r = 0.04, 95% CI; -
0.04 to 0.12, and -0.01; -0.12 to 0.11, in women and men).
Serum creatinine (continuous variable) and odds for 
diabetes
The unadjusted GAM analysis suggested a piecewise lin-
ear relationship between serum creatinine and T2DM
(figure 1). Piecewise linear regression models showed
that each 1 μmol/l increase in serum creatinine was asso-
ciated in women with 6% (95% CI; 3%-8%) lower odds of
type 2 diabetes below a serum creatinine level of 69 μmol/
l, whilst in men it was associated with 7% (95% CI; 2%-
13%) lower odds of type 2 diabetes below a serum creati-
nine level of 72 μmol/l (table 2; Additional file 1). Above
these breakpoints the level of serum creatinine did not
reduce the odds further. Adjustments for known non-
modifiable and modifiable risk factors (models 2-3) left
the piecewise effect for both women and men largely
unchanged. The results were unaffected by the substitu-
tion of WHR for either lean body weight or BMI (data not
shown). In the fully adjusted model, which included
serum magnesium, albuminuria and insulin resistance
(model 4), the piecewise effect for men was statistically
non-significant, yet this remained present for women.
The effect of serum creatinine was no longer present in
men, but among women the inverse relationship between
serum creatinine and T2DM remained highly significant
before the breakpoint.
Sub-group analysis of data from the 495 patients com-
pleting the physical activity questionnaire showed similar
results (models 1-3), and the results were not altered by
further adjustment for self-reported hard physical activ-
ity (data not shown).
Serum creatinine (dichotomized variable) and odds for 
diabetes
The breakpoints were located in the proximity of the
median serum creatinine for men (73 μmol/l) and women
(61 μmol/l). Above these breakpoints the odds of T2DM
did not change, whereas the odds increased with decreas-
ing creatinine levels below the breakpoints. For simplifi-
cation, we therefore also dichotomized creatinine at the
medians in order to estimate the average effects of creati-
nine levels below the breakpoints. Women with creati-
nine levels below the median had an approximately 50%
increase in the odds of T2DM; OR 1.56 (1.09, 2.25) for the
unadjusted model and 1.47 (0.93, 2.32) for the fully
adjusted model. Men with creatinine levels below the
median had an approximately 75% increase in odds of
T2DM; OR 1.73 (1.09, 2.79) in the unadjusted model and
1.76 (0.92, 3.39) in the fully adjusted model.
Discussion
Statement of principal findings
The results of the present analysis confirm in a popula-
tion of 1, 017 consecutive morbidly obese subjects with
an eGFR > 60 ml/min our initial hypothesis of an inverse
association between serum creatinine and T2DM. Each 1
μmol/l increase in serum creatinine was associated in
females with 6% (95% CI; 3%-8%) lower odds of T2DM
below a creatinine level of 69 μmol/l. In the case of men it
was associated with 7% (95% CI; 2%-13%) lower odds of
T2DM below a creatinine level of 72 μmol/l. After these
breakpoints increasing creatinine levels did not decrease
the odds further. Adjustments for known modifiable and
non-modifiable risk factors left the piecewise effect for
both women and men largely unchanged.
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Our findings extend the results from a previous study
which demonstrated a significant association between
low serum creatinine levels and incident T2DM in Japa-
nese non-obese (mean BMI 23.4 kg/m2) middle-aged
men (40-55 years) [10], and show this association to be
valid for prevalent T2DM in Caucasian morbidly obese
women and men between 18 and 75 years of age. In addi-
tion, our data indicates that among morbidly obese sub-
jects there is a piecewise linear relationship between
serum creatinine and T2DM, with an inverse effect
before a breakpoint of approximately 70 μmol/l and no
effect above.
Lorenzo et al. recently showed that subjects who had a
high GFR (MDRD mean eGFR 121 ml/min/1.73 m2) had
a two-fold increased adjusted odds, OR 2.29 (1.06-4.97),
of incident diabetes as compared with those who had a
normal/near normal GFR (mean eGFR 80 ml/min/1.73
m2). Although our diabetic patients did not have higher
creatinine clearance than their non-diabetic counter-
parts, they were on average 8 to 9 years older, and creati-
nine clearance tends to decrease with age. This could
explain the apparent absence of association between cre-
atinine clearance and diabetes in the present study, and,
thus, we cannot exclude the possibility that glomerular
hyperfiltration, which is commonly observed in non-pro-
teinuric T2DM patients [31,32], might partly explain our
results.
Strengths and limitations
The validity of our study is strengthened by the inclusion
of a relatively large number of consecutive morbidly
obese patients. In addition, the piecewise linear relation-
ship between serum creatinine and T2DM remained sta-
ble after adjustments for multiple risk factors. In terms of
weaknesses, the cross-sectional design of the study
implies that we cannot establish a cause-effect relation-
ship, whilst the exclusion of non-Caucasian participants
has meant that we are unable to generalize our results to
non-Caucasian populations.
In addition, lean body weight, glomerular filtration rate,
and creatinine clearance were estimated rather than mea-
sured with gold standard methods [8,16,21,22]. Further-
more, we did not use the oral glucose tolerance test which
has a higher sensitivity than fasting blood glucose in the
diagnosis of diabetes. However, this is probably not a
major problem since fasting glucose has been shown to
identify the great majority of morbidly obese patients
with unknown diabetes [33]. Finally, the weaker associa-
tions and less consistent results among men might be
Figure 1 Relationship between serum creatinine and type 2 diabetes. Left: Estimated functional relationship between serum creatinine and 
T2DM using Generalized Additive Models (GAM). Breakpoints and 95% CIs from a piecewise linear models at the bottom. Right: Corresponding odds 
ratios (approximately 0.90 below and 1.0 above the breakpoints). Given the large uncertainty in the location of the breakpoints the graph does not 
take the shape of the idealized step function a piecewise linear model assumes, but has a marked transition face.
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(type II error).
Possible explanations
We did not explore possible mechanisms. It might, how-
ever, be speculated that low serum creatinine mirrors low
muscle mass [7,9], which itself has been associated with
insulin resistance [34] and the metabolic syndrome [5],
and accordingly provides a higher risk of T2DM. Our
study, however, does not support this notion given both
that lean body weight, body weight and BMI were not
particularly low among patients with low serum creati-
nine. By contrast, serum creatinine was actually nega-
tively correlated with BMI and not significantly
correlated with lean body weight. Finally, adjustments for
BMI or lean body weight did not attenuate the inverse
relationship between creatinine and T2DM.
Unanswered questions and future research
Longitudinal studies of both obese and non-obese popu-
lations are needed in order to further investigate whether
serum creatinine is causally linked to T2DM or whether it
rather represents a measure of the disease [35]. Such
studies should also explore potential mechanisms and
clinical implications.
Conclusion
Low serum creatinine is a predictor of type 2 diabetes in
Caucasian morbidly obese patients independent of age,
gender, family history of diabetes, anthropometric mea-
sures, hypertension, and current smoking.
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